The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation
Open Access
- 1 December 2010
- journal article
- review article
- Published by Elsevier in Kidney International
- Vol. 78 (11) , 1075-1079
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinomaBMC Cancer, 2010
- The role of mTOR in memory CD8+ T‐cell differentiationImmunological Reviews, 2010
- Carboxy Terminal Tail of Polycystin-1 Regulates Localization of TSC2 to Repress mTORPLOS ONE, 2010
- Noncanonical TGF-β pathways, mTORC1 and Abl, in renal interstitial fibrogenesisAmerican Journal of Physiology-Renal Physiology, 2010
- Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesisInternational Journal of Cancer, 2009
- Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathwaysLiver Transplantation, 2009
- Rapamycin fed late in life extends lifespan in genetically heterogeneous miceNature, 2009
- Distinct Roles for Mammalian Target of Rapamycin Complexes in the Fibroblast Response to Transforming Growth Factor-βCancer Research, 2008
- The AKT–mTOR axis regulates de novo differentiation of CD4+Foxp3+ cellsJournal of Experimental Medicine, 2008
- Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cellsBlood, 2005